Hybrigenics

Contact
hybrigenics.com
+33158103800

Hybrigenics

3-5 impasse Reille
75014 Paris
France
+33158103800
hybrigenics.com
Contact
Profile Products News
Contact

About Hybrigenics

Hybrigenics is a bio-pharmaceutical company in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Read more about Hybrigenics
Facts about Hybrigenics
  • Industry : Pharma

Product portfolio of Hybrigenics

Product portfolio

Show all

News about Hybrigenics

Hybrigenics

18-Aug-2015 | research and development

Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States

Hybrigenics announces the Orphan Drug designation by the American Food and Drug Administration of inecalcitol for the treatment of acute myeloid leukemia ( ...

Read news
Hybrigenics

13-Sep-2012 | research and development

Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia

Hybrigenics announced the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL). World-wide, about 130 ...

Read news
Hybrigenics

11-Oct-2011 | business & finance

Hybrigenics and Servier enter into a licence and research collaboration agreement in oncology and other therapeutic fields

Hybrigenics will receive EUR four million over three years to identify new deubiquitinating enzymes and screen their inhibitors, and is further eligible to success milestones

Read news
Hybrigenics

07-Oct-2011 | people

Hybrigenics appoints Dr Alain Munoz to its board of directors

Hybrigenics announced the appointment of Dr Alain Munoz to its board as a non-executive independent director. Dr Munoz replaces Dr Bernhard Ehmer, ...

Read news
Hybrigenics

15-Jul-2011 | research and development

Hybrigenics' inecalcitol inhibits the growth of human hormone-dependent prostate cancer cells in vitro and in vivo

Hybrigenics announced the publication of a scientific article by Dr Ryoko Okamoto and co-authors in the peer-reviewed International Journal of Cancer. ...

Read news
Hybrigenics

26-Jan-2011 | research and development

Hybrigenics receives green light for its European patent on high therapeutic doses of inecalcitol

Hybrigenics (ALHYG) announced it has received from the European Patent Office the official notification of its intent to grant Hybrigenics’ patent on ...

Read news
Hybrigenics

07-Dec-2010 | people

William Vickery joins Hybrigenics as Head of Corporate and Business Development

Hybrigenics announced it has hired William Vickery as Head of Corporate and Business Development, a newly created position. William worked for five years ...

Read news
Hybrigenics

04-Nov-2010 | research and development

Hybrigenics develops new oral formulations of inecalcitol

Hybrigenics seeks patent protection until 2030 for innovative oral formulations optimized for the delivery of high doses of inecalcitol

Read news
Show more news about Hybrigenics

Here you will find Hybrigenics